A design for death: meeting the bad boy of the euthanasia movement | 1843 – The Economist 1843

Its a sunny autumn morning in the Jordaan, Amsterdams chocolate-boxiest district. Over tea in a modishly renovated maisonette, a voluble Australian 72year-0ld wearing round glasses and fashionable denim is regaling me with his new-year plans, which involve an elegant gas chamber stationed at a secret location in Switzerland and a happily dead body.

My hosts name is Philip Nitschke and hes invented a machine called Sarco. Short for sarcophagus, the slick, spaceship-like pod has a seat for one passenger en-route to the afterlife. It uses nitrogen to enact a pain-free, peaceful death from inert-gas asphyxiation at the touch of a button. With the help of his wife and colleague, the writer and lawyer Dr Fiona Stewart, Nitschke is ushering the death-on-demand movement towards a dramatic new milestone and their enthusiasm is palpable.

Weve got a number of people lined up already, actually, says Nitschke, whose unique CV (and previous occupation as a registered physician) has earned him the nickname Dr Death. The front-runner in the one-way journey to Switzerland is a New Zealander whom Nitschke has known for years. Shes not terminally ill, but is becoming increasingly disabled by macular degeneration something she finds intolerable after a lifetime of reading for pleasure. Shes also got an ideological, philosophical supportive commitment to the idea, explains Nitschke. Shes coming from a long way because she likes the concept and she sees it as the future.

Whether that future is utopian or dystopian depends on your perspective. Nitschke has twice been nominated for Australian of the Year for his work with Exit International, the end-of-life choices information and advocacy organisation he founded in 1997; activities include the publication of The Peaceful Pill, a continuously updated directory of information on how to end it all. But over the past two decades, members of the medical, psychiatric and even the pro-voluntary euthanasia communities have come to reject his brand of increasingly strident some say extreme advocacy for what he terms rational suicide: an individuals inalienable right to die in a manner of their choosing. His one time ally, the former UN medical director Michael Irwin, has branded him totally irresponsible for telling people how to obtain drugs that could help them end their own lives. And in August 2019 the grieving daughter of a man who took his life after contact with Exit International denounced Nitschke, saying the information you put out kills people who are not in a rational state of mind to make that decision.

Nitschke says he doesnt want to make a load of money from it, but theres Silicon Valley swagger in his latest projects ambition to disrupt the business of elective death through technology. The Sarco concept came to Nitschke while watching "Soylent Green", a 1970s sci-fi movie in which Charlton Heston, disgusted by a world ravaged by global warming, seeks euthanasia in the serenity of a customised government clinic. Its set in 2022. Eventually, Nitschke wants the 3D-printed Sarco to be accessible on demand to anyone, anywhere a sort of cosmic Uber into the great beyond. But for now, hes taking his invention to Switzerland because its the only jurisdiction worldwide in which, so long as theres no malicious purpose, assistance in a suicide is not a crime.

Nitschke and Stewart are much jollier than youd expect the right-to-die movements only power couple to be. Theyre full of well joie de vivre and arch banter about everything from Brexit to the roadworks that have denuded the front of their home of a beloved creeper. If its not dead, boy is it doing a bloody good impression of being dead, observes Nitschke, correctly. Stewart is at the kitchen table, processing applications from her laptop, and asking correspondents for proof of age. Officially, membership to Exit is restricted to the over 50s, and its members are mostly in jurisdictions where neither assisted suicide nor euthanasia are available which is to say, most of the countries in the world. Im the door bitch, she jokes.

Stewart had been a pro-choice advocate in Australia before meeting Nitschke at a festival of ideas in Brisbane in 2001.Later, she would be horrified by the state of his nascent organisation. She said, This is a mess youre not paying enough tax, your business is a shambles and it needs proper management. says Nitschke. She turned the whole thing around. I cant do much without her.

One of those opposed to Sarco is Paul Biegler, adjunct research fellow at the Monash Bioethics Centre in Victoria. You can make an argument that people have got a right to control the time of their death, he tells me over Skype, later. You could make an argument that rational suicide in the absence of a terminal illness is a defensible option for some people. But it really is a quantum leap to go from saying that people have a right to choose the time and nature of their dying to providing a mechanism for that to happen.

A comprehensive assessment of worldwide data in 2016 showed that, in areas where euthanasia or physician-assisted suicide are legal, 0.3-4.6% of deaths result from them, with more than 70% of cases involving patients with cancer. The report described these numbers as an indication that despite growing legalisation the practice remains rare. The Netherlands relatively permissive law stipulates that to qualify for either procedure an applicant must be shown to be experiencing unbearable suffering from which there is no prospect of recovery with no reasonable alternatives available to end that suffering. It has been criticised for not making a distinction between physical and mental distress, which could, in theory, justify euthanasia for psychiatric patients. Switzerlands law is looser foreigners can travel there and legally access physician-assisted suicide. The only two legal requirements a candidate is required to satisfy are the intention to end their life and soundness of mind. The general approach [for the latter] has been to get a ticket of approval from a psychiatrist, notes Nitschke.

The Sarco project bore fruit at the same time as subtle legal developments in Switzerland. Although theres nothing in Swiss law to state that a person must be terminally ill to be eligible for assisted suicide, in practice, says Nitschke, groups such as Dignitas have chosen to further medicalise the legislation, he says, because the only way they could get a doctor to prescribe [the lethal dose of the barbiturate] Nembutal was for the person to say they were sick.

This, he thinks, is specious and evidence of the medical professions creeping paternalism, which he finds abhorrent. [Doctors are] always there, setting themselves up as the gatekeepers when it comes to areas of human endeavour that they should have no role in because when you medicalise something youve got to have a medical controller, he says.

The great irony of Nitschkes career, in his view, is that he seems to spend as much time arguing with people on my own side as he does weathering the rebukes of the born again Christians. He recalls being denounced by Dignity in Dying (in its former incarnation as the Voluntary Euthanasia Society) after he was detained, then released, by authorities at Heathrow airport on his way to host Exit workshops in the UK whilst carrying equipment for testing the safety of Nembutal, the barbiturate most often used for lethal injections, which terminally ill individuals were starting to obtain online from questionable sources.

They came out and said I was a danger to the movement. I found that annoying but I suppose what we were seeing was a difference in philosophy. I was telling people: get your own drugs, test your own drugs, be in control; they were saying: change the law, convince the politicians...

Its undeniable that Nitschkes campaigns have exhibited a certain PR-savvy pizzazz. He is the originator, no less, of the euthanasia flash mob, which took place to celebrate his 70th birthday and 20 years of Exit International (soundtrack: Bon Jovis "Its My Life", naturally). When he announced plans for Sarco, it was dismissed by some, says Nitschke, as a stunt, or some virtual creation in someones mind that didnt have any prospect of physical reality.

I can attest that the machine exists, having had the singular experience of reclining on a prototype at Nitschkes workshop on an industrial estate in Hillegom, South Holland, amidst the incongruous spring blaze of the tulip fields. Plus, scratch the surface of his provocative patter and theres a person a patient lurking behind each of his convictions.

Even aged 18, Nitschke demonstrated a flair for taking the law into his own hands after thieves stole the radio from his car, which was parked outside a dance. The police told him it was too small an affair to pursue so Nitschke spent two Saturday nights hiding in the boot with a .22 caliberrifle waiting for the thief to return. They did, and Nitschke marched them to a telephone and called the police, who arrested the thief and retrieved the stolen transistor.You should solve your own problems is how Id put it, says Nitschke.

Nitschke studied physics at the University of Adelaide before heading to the Northern Territory to work as an Aboriginal land-rights activist. Having studied for his medical degree with, he says, the intention of curing himself of hypochondria, in 1996 he became the first doctor in the world to administer a legal, lethal voluntary injection under the short-lived Rights of the Terminally Ill Act which, astonishingly, made the statute books in the Northern Territory by one vote.

Suddenly we had a law which meant terminally ill people could legally seek help from a doctor to die, he recalls. And when a patient came to me who was eligible, because he was dying of prostate cancer, as much as I was passionate about his right to die, I didnt want to be the one to do it, you know, so I built a machine that would downgrade euthanasia into assisted suicide. I would load it up and put the needle in the vein, all that stuff, but he was the one pressing the button.

That patients name was Bob Dent and Nitschkes invention, the Deliverance Machine listed on the Wikipedia page for notable euthanasia devices in history and now on display in Londons Science Museum lasted eight months and ended the lives of three more people before the law was overturned and assisting in a suicide became a serious crime again.

The other important aspect of the Deliverance and this certainly doesnt apply to Sarco was that it meant the user was able to die in his wifes arms, says Nitschke. The machine didnt take up much space so he was able to press the button, push the machine away and hold his wife, his usually robust voice crackles. I was on the other side of the room, he says.

Initially, Nitschke ran Exit workshops exclusively for the terminally ill. His self-described big, blinding road to Damascus change came courtesy of a French academic from Perth named Lisette Nigot, whom Nitschke met in 1999 when she was 76. She had no desire to live to see 80, and repeatedly approached Nitschke asking for information about suicide drugs.

I always said to her, thats ridiculous: youre not sick, go on a world cruise or write a book. And one day she said: Mind your own business. I make this decision you run around imposing your template on other people of what a life worth living is and dole out your information only to those people you think meet your criteria. Youre the worst example of insufferable medical paternalism Ive ever met.I immediately crumpled and fell apart and agreed with her. It really affected me. Theres a photograph of Nigot whose 2002 suicide-note declared Nitschke to be her inspiration on the wall of the workshop in Hillegom.

Nitschke developed Sarco with the help of Haarlem-based industrial designer Alexander Bannink. My original design looked more like a bathtub, says Nitschke, whereas Alexander really pushed the idea of making it resemble a vehicle, to give the sense of going somewhere. Engaging suppliers for the project has been interesting. When we first went to see a company down in Vlaardingen about building these strange aluminium tanks, I said to them, Im building some sort of death machine, do you want one of your logos on the side of it? They declined.

Sarcos raison dtre, admits Nitschke, is aesthetic. It obviates what he calls the yuck factor inherent in other tools of peaceful suicide, such as the humble plastic bag and gas. Thats just as efficient, he says. You can tell people over and over and over, as I do in my workshops, that its cheap, reliable, quick and legal, but they say, I dont care if its a peaceful death, I do not like the look of it and I dont want to be found like that.

Sarco, meanwhile, is positively Instagrammable. A sleek conveyance that wouldnt look out of place in a Tesla showroom, it consists of a detachable capsule a coffin, essentially mounted diagonally on a stand. Once inside, its user presses a button, prompting the release of nitrogen from a store-bought canister. From a physiological point of view, it is peaceful, says Nitschke. Its not the same as a rope around the neck, a pillow in the face or a head underwater these are mechanical obstructions to breathing and theyre terrifying, let me tell you.

Unlike previous Nitschke-devised death technologies, Sarco does not require the procurement or prescription of drugs. This is handy because Nitschke is no longer a doctor, having publicly burned his medical licence in 2015 following a dispute with the South Australian chapter of the Medical Board of Australia. It suspended Nitschke before offering to reinstate him providing he fulfil 26 criteria which included refraining from talking about euthanasia. Shortly afterwards, Nitschke and Stewart moved to the Netherlands on an entrepreneurial visa.

Then came the elective death in May 2018 of Nitschkes friend, the 104-year-old botanist David Goodall, who refused to declare any serious condition beyond being tired of life but was nevertheless allowed to kill himself by lethal infusion at the Life Circle facility in Basel. That set a precedent, says Nitschke.

Nitschke and his lawyers began the process of setting up what he vaguely calls an organisation in Switzerland to facilitate the use of Sarco for those who want to end it all for whatever reason. For now, hes keeping the specifics of the facility and its whereabouts close to his chest for fear of sabotage, but he says hes been talking to amenable local psychiatrists whose participation hell need because the soundness of mind criterion still stands and is confident of success.

Its late November Black Friday, in fact when I call Nitschke on his mobile for an update. He and Stewart are on the road with Sarco in tow, having retrieved a display model from a flooded Venice, where it has been on show at the Palazzo Michiel as part of the Venice design festival since May (pictured above).It was bloody awful, he says of the devastation in Venice. Fortunately Sarco was on the palazzos first floor, but still it had to be carried by people wearing thigh-high waders, put on a barge and floated out of the place.

I ask whether Nitschke is feeling nervous about a debut for which there can, after all, be no dress rehearsal. There is a great deal of apprehension and nervousness, he affirms, and I can sense it building now as I watch the calendar days ticking down. Im getting more and more anxious about it because I well and truly recognise that theres a lot hinging on this for other people whose wishes are very important to me and, while I want things to run smoothly theres always the possibility of some bizarre eventuality you cant predict. But once Ive got the comfort of seeing the successful initial uses of the machine I think Im going to be very pleased indeed.

He suspects the reaction against Sarco has been so strong because the whole ethos of the device flies in the face of the current Western paradigm, which dictates that all human effort and endeavour should be directed towards living longer at all costs, and any death is perceived as some fundamental failure that must be conducted shamefully, privately and in secret.

He thinks technology is affording us the opportunity to consider how the end of life might be reframed as a cause for some celebration or at least a momentous event, as it has been regarded by other cultures and in times gone by.

I ask the obvious question: what a successful death might look like in his own case. It would depend, he says, on the circumstances.But I know what I dont want. I dont want to be stuffed full of tubes with doctors hovering over me, pleased with themselves for keeping my heart beating for another five minutes, eking out every last painful second. That, to me, is dystopia.

Read more:

A design for death: meeting the bad boy of the euthanasia movement | 1843 - The Economist 1843

Pro-lifers gear up for fight against legalization of euthanasia in Ireland – Live Action News

Irish pro-lifers have been embattled ever since the repeal of the Eighth Amendment last year, which legalized abortion. Now pro-lifers in the country are readying themselves for a fight on a new life issue, as a poll by the Journal shows that three in five support legalizing euthanasia.

President of the Society for the Protection of Unborn Children (SPUC) lamentedthe creeping erosion of pro-life protections in the Republic of Ireland:We have witnessed dreadful changes in Ireland in recent years in relation to abortion. Now we are seeing a further threat to innocent lives looming on the horizon. We need to combat these threats by exposing the reality of assisted suicide. Evidence from around the world shows that the so-called right to die quickly becomes the duty to die.

The recent media spotlight on euthanasia comes from Vicky Phelan, who is known in Ireland for her exposure of massive deficiencies in a government cervical cancer screening program. Because of these mistakes, she missed a critical diagnosis window and is currently suffering from terminal cervical cancer. Now, 45-year-old Phelan has emerged as the latest face of the euthanasia movement in the country. According to the Journal, the mother of two told the Irish Mail on Sunday that she would avail herself of the procedure, and that she would campaign for others who want it. Euthanasia and assisted suicide are currently illegal in Ireland.

READ:Three reasons a Dutch ethicist changed his mind about assisted suicide

As reported by Extra.ie, Phelan explained that she believes she only has two years left to live. I would be pro-euthanasia, definitely. I would hate to be in a position where I was in a lot of pain or lingering, as can happen a lot, that people are waiting for four or five days for somebody to die, she said. She portrayed terminal illness as intolerable for both family and patient: Its terrible for the patient. Its terrible for the family having to sit and watch their loved one [dying in pain]. Its not a nice sight to see people when theyre dying.

Unfortunately, Phelan isnt a minority here. According to a poll conducted by the Journal, 63% are in favor of assisted suicide or euthanasia, making it the next major pro-life target in Ireland. Just 16% reported they would not support the legalization of euthanasia in Ireland.

What Phelan and supporters dont understand is that legalizing euthanasia always ends up hurting societys most vulnerable. In countries like The Netherlands, euthanasia legalization nearly two decades ago initially began with hard cases like Phelans in mind. But the slippery slope of legalizing euthanasia has led to the endangerment of those with mental illness, the elderly, and even children. Its why former euthanasia activists like Dutch ethicist Theo Boer so ardently warns other countries to avoid going down this path.

A similar case before the high court failed in 2013, but the conversation has since re-emerged and with major countries like New Zealand putting it on the table, it could force the issue in Ireland.

Like Live Action News on Facebookfor more pro-life news and commentary!

Originally posted here:

Pro-lifers gear up for fight against legalization of euthanasia in Ireland - Live Action News

With voluntary assisted dying not an option, Laura Henkel is heading to Switzerland to ‘die with dignity’ – ABC News

Updated December 15, 2019 15:11:40

Laura Henkel is about to embark on the last journey of her life.

While pain and exhaustion have become an inescapable part of this 90-year-old's life, she has not been diagnosed with a terminal illness.

"I think old age is a terminal illness because you can't cure it like a disease, you can't mend it like a broken bone," she said.

"It's only going to get worse and there's nothing you can do about it.

"I don't want to put my family through the terrible experience that I had with my own mother, where she suffered for 15 years with dementia and loss of dignity.

"I vowed 40 years ago that I would not die like that."

Voluntary assisted dying in Australia is not an option for Ms Henkel.

While Victoria and Western Australia have passed assisted dying laws, they only apply under a strict set of circumstances.

In both states, applicants must be terminally ill with intolerable pain, and likely to die within six months, or 12 months for neurodegenerative diseases.

It is illegal in all other states and territories.

Determined to end her life on her own terms, Ms Henkel is packing her bags for Switzerland.

"I want to end my life with dignity," she said.

"I would far rather stay here in my home and die here in my home with my family around me, but here in New South Wales I'm not allowed to. I'm not allowed to die."

Ms Henkel's daughter, Cathy Henkel, and granddaughter, Sam Lara, are supporting her decision and will be by her side when she dies.

"Well, of course it conflicts when your mum tells you she wants to die," Cathy Henkel said.

"But she very quickly explained to me that her quality of life had declined to such a degree, and she told me about her own mother and not wanting to end up like her, and I could see that daily suffering."

Ms Henkel has asked her filmmaker daughter and granddaughter to document her euthanasia journey.

It is a challenging task for a loved one grappling with her grandmother's decision.

"I feel a million emotions on an hourly basis," Ms Lara said.

"But in the long-term, I think the upsides to this choice are definitely going to outweigh the challenges.

"The best aspects of Laura's choice have definitely been the chance to say goodbye.

"We've been able to do a lot of bucket-list things."

The three generations of women hope the film will start a dialogue in Australia about the laws around voluntary assisted dying.

"What Laura is doing is forcing us to talk about death and to talk about the end of life for the elderly and what options they have and what options they don't have," Ms Lara said.

"It is incredibly challenging, and I know because I've lived it.

"It is going to bring up a lot of emotion and conflict in people [but] I don't know if that's necessarily a bad thing."

While Ms Henkel has made her position clear, the issue of voluntary assisted dying in Australia is a complex and often divisive issue.

Margaret Sommerville is a professor of bioethics at the Catholic University of Notre Dame in Sydney.

"People believe it's their right, it's their decision and this is what they want to do, but we also have to think about what impact would that have in our society in general," Professor Somerville said.

"We know that people who feel like that, when they get fully adequate care and support, a very large number of them change their mind.

"This is even people who have asked for and consented to euthanasia in jurisdictions where it's legal."

The Australian Medical Association's statement position is that doctors should not be involved in ending a person's life.

It recognises the broad range of views within the medical profession and the broader community, but says laws relating to euthanasia and physician-assisted suicide are, "ultimately a matter for society and government".

For Laura Henkel, the fear of losing autonomy through a stroke or dementia outweighs the fear of death.

"I don't want to die in hospital, [and] I don't want to die in an old-age home," she said.

"A sportsman is allowed to say, 'Look, I've had enough'. You may say, 'Oh, but he can still play beautifully why does he want to retire?' But he suddenly feels he's had enough, so you accept that, so why not accept that life is the same thing?

"Just about everybody says, 'I would like to die in my sleep', and that's precisely what I'm going to do.

"I'm going to go to sleep, and then I will die."

Topics:aged-care,health-policy,euthanasia,death,pain,community-and-society,ballina-2478,lismore-2480,switzerland

First posted December 15, 2019 09:11:44

Read the original here:

With voluntary assisted dying not an option, Laura Henkel is heading to Switzerland to 'die with dignity' - ABC News

Over Three Fourths Of Icelanders Support Right To Assisted Dying – Reykjavk Grapevine

Photo by

Christian Bickel/Wikimedia Commons

A poll conducted in November this year shows that 77.7% of Icelanders support the practice of assisted dying. The study was made by Lfsviringar (Life of Dignity), an Icelandic association for the education about assisted dying, and conducted by Maskna. Icelanders also showed to favour the Dutch method for the practice.

In 2017, Lfsviringar was born with the purpose of creating awareness and bring forward discussion and education into the subject of euthanasia. The theme was not new to Icelandic society, for already in a 2015 poll 75.5% of the respondents showed support for the practice. Also in 2017, seven members of Parliament, from different parties, came forward in an effort to legalize assisted suicide in the country. For their proposal to be successful they needed 58 letters of support, they received some, including one from the National Association of Senior Citizens, but failed to go forward with the bill.

The Dutch method is the one that retains more popularity between voters. The Termination of Life on Request and Assisted Suicide (Review Procedures) Act is in practice in The Netherlands, Belgium, Colombia, and Luxembourg. The Dutch were the first to legalise the practice in 2002, making assisted suicide viable if a physician holds the conviction that the request by the patient was voluntary and well-considered if he holds the conviction that the patients suffering was lasting and unbearable, and if the patient holds the conviction that there was no other reasonable solution for the situation he was in.

From the 2015 poll to the one conducted this year, there were changes in the way that the question was asked, making it more detailed. While in 2015, Icelanders had to answer to Are you in favour or against that an individual can get help to end their life if he has an incurable disease (palliative death)?. This year, the people surveyed were asked to respond the following Do you agree or disagree that an individual can be helped to end their life (assisted dying) if they are suffering from a condition or disease that has been assessed incurable and that they are experiencing to be unbearable?.

Granted that, in 2019, the majority chose to respond positively, 6,8% said they were highly or rather opposed, and 15.4% were not sure. When questioned about why they opposed assisted suicide, some of the respondents said that it was contrary to the moral and professional obligations of doctors (23.5%), others believed that palliative care was sufficient to alleviate suffering (21.7%), some even stated it was against their moral beliefs (20.4%), but only 3.6% claimed religious reasons. The top concern between participants was that the legalisation of the practice would lead to the misuse of it.

Curiously, people from different age groups, locations and even political parties responded very differently to the survey. While 85% of 18 to 29-year-olds responded in agreement, only 63.4% of people older than 60 years were on the same page. People in Reykjavk represented the biggest percentage of people answering in favour (80.7%), while it was in the citys neighboring municipalities where the lowest percentages were seen (74.4%), followed by the north of the country (75.5%). Regarding the political views of the participants, a great percentage of The Pirate Partys voters (86.8%) were positive to the poll in contrast with the voters for The Progressive Party (68.3%).

Assisted suicide raises a lot of questions from all sides of the subject. While some believe it shouldnt be done by medical professionals because they consider it goes against the Hippocratic oath, others would say that if these professionals swear to do no harm, the assisted suicide of patients in irreversible pain is in agreement with the oath.

In 2017 an Australian reader of The Grapevine responded to one of our articles on the same subject with his own experience. He wanted other readers to know that enforced prolonged life, when the quality of life is lost, is a fate far worse than death.

Related

Link:

Over Three Fourths Of Icelanders Support Right To Assisted Dying - Reykjavk Grapevine

Provincial govt tries to bully Canadian hospice into killing sick patients – Lifesite

DELTA, British Columbia, December 12, 2019 (LifeSiteNews) British Columbias government is threatening to penalize a non-faith-based hospice if it fails to follow its directives and allow its patients to be killed on-site through a medically-assisted death program.

The province could go as far as to shut down the Delta Hospice Society, which operates the 10-bed Irene Thomas Hospice in Ladner, BC, says Alex Schadenberg of the Euthanasia Prevention Coalition.

New Democratic Party (NDP) health minister Adrian Dix has given the society until Thursday to produce plans to comply with the Fraser Health Authoritys policy that all its facilities excepting faith-based institutions that can object on religious grounds provide euthanasia, the Globe and Mail reported.

Its the latest turn in a long-running battle that began in September 2016, when Fraser Health Authority adopted its policy on euthanasia, euphemistically referred to as medical aid in dying (MAiD), which the Justin Trudeau Liberal government legalized that June.

Hospice founder and then-executive director Nancy Macey refused to allow euthanasia at Irene Thomas, arguing that patients would need to be transferred to another facility to be killed because lethally injecting them was incompatible with palliative care and violated the hospices constitution, which states that it will not hasten a patients death.

The hospice is under contract with the health authority, which funds it $1.3 million annually, or slightly less than half its operating budget the rest of which comes from private donations and owns the land on which the building sits, which it leases to the hospice, according to the Vancouver Sun.

Fraser Health Authority then issued an edict in February 2018 that the hospice provide euthanasia onsite, but the society said it would not do so.

Macey and Janice Strukoff, an administrative leader for society, told the Vancouver Sun at the time that euthanizing patients not only is against the hospices constitution, but also stoked fears and anxieties of vulnerable patients and would traumatize not only them, but also staff and volunteers.

Hospice palliative care is not about hastening death and we object to the bullying currently taking place in B.C., Strukoff said.

The health authority then mandated in September 2018 that hospices could not transfer a patient to another facility to be euthanized, according to the Vancouver Sun.

And in September 2019, the hospice board fired Macey and voted to allow euthanasia, it reported.

However, following a membership drive, a new board was elected at the November 28 annual general meeting. It voted to reverse the policy to allow euthanasia, arguing that doing so was against the societys constitution, dismissed the acting executive director, and appointed a new one.

The Canadian Society of Palliative Care Physicians and Canadian Hospice Palliative Care Association backed the Delta societys decision in a joint November 27 Call to Action.

Hospice palliative care and MAiD substantially differ in multiple areas including in philosophy, intention and approach. Hospice palliative care does not seek to hasten death or intentionally end life, the statement said.

MAiD is not part of hospice palliative care; it is not an extension of palliative care, nor is it one of the tools in the palliative care basket. National and international hospice palliative care organizations are unified in the position that MAiD is not part of the practice of hospice palliative care, it added.

Fraser Health Authority responded to the decision by insisting the hospice had to comply with its policy and met with members of the board on December 5. Now Dix is suggesting the province will pull funding if not more drastic punishment if the hospice doesnt bow to the euthanasia rule.

[W]e do live in a free society, Dix told the Globe and Mail.

Delta Hospice Society can decide that it doesnt want to continue to receive support from the Fraser Health Authority in its mission. They can choose to do that. You can absolutely have it your way. But you cant have it both ways.

But Schadenberg says the minister and the health authority are overstepping their roles by forcing and bullying the hospice to provide euthanasia.

He has launched a petition to Dr. Victoria Lee, president of the Fraser Health Authority, and to minister Dix supporting the society.

The results of this battle will be far-reaching, Schadenberg told LifeSiteNews.

If the Delta Hospice closes, the residents of Delta will lose the 10-bed hospice that is known for providing excellent end-of-life care, he said.

If the Delta Hospice is forced to do euthanasia, then all Canadian hospice groups will be forced to do euthanasia.

To sign the EPCC petition supporting Delta Hospice, go here.

Continue reading here:

Provincial govt tries to bully Canadian hospice into killing sick patients - Lifesite

Priest reminds public: ‘Honor the sanctity of life’ – INQUIRER.net

Fr. Prudencio Operiano calls on the public to honor the sanctity of life during the fourth day of Misa de Gallo on Thursday, December 19, 2019, at the National Shrine of Saint Joseph in Mandaue City. CDND Photo / Raul Tabanao

MANDAUE CITY, Cebu Thursday mornings homily on the fourth day of Misa de Gallo here centered on the Catholic Churchs teachings against suicide, abortion, and euthanasia or mercy killing.

Fr. Prudencio Operiano of the National Shrine of Saint Joseph in Mandaue City reminded parishioners on Thursday, December 19, that taking ones life in any way is a sin because it disregards the sanctity of human life.

Ang kinabuhi gikan sa Ginoo. Ang kinabuhi sagrado ug sumala pa ni (Life comes from God. It is sacred and according to) Pope Saint John Paul II: All stages of life, from womb to the tomb, is sacred,' Operiano said.

While it is the mothers who carry unborn children, Operiano said their lives still belong to God.

The priest also emphasized that ending ones life is also a sin.

Tungod kay sagrado ang kinabuhi sa tawo, angay kining tahuron. Dako kaayong sala ang paghikog. Dako kaayong sala ang pag-abort o ang pagkuha sa kinabuhi sa bata,Operiano said.

(Because life is sacred, it must be respected. Its a mortal sin to commit suicide. Its a mortal sin to abort or end the life of a child.)

Operiano also called on families to refuse to perform euthanasia or mercy killing for their sick family members.

The priest also called on parishioners to give value to every life in the society regardless of economic status and other social standards.

As Christmas Day draws near, Operiano said one of the greatest blessings a person could receive is the guidance to see how valuable other persons are.

Makakakita gani ta sa atong silingan nga tawo, atong hinumduman nga siya angay respetohan, angay higugmaon, tabangan ug kaluy-an, Operiano said.

(When we see our neighbors as fellow men, let us remember that he deserves respect, love, help and compassion.) / celr

Read Next

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Read the rest here:

Priest reminds public: 'Honor the sanctity of life' - INQUIRER.net

New policy could allow doctors to euthanize Alzheimer’s patients without their active consent – TheBlaze

The government of the Canadian province of Qubec is considering allowing doctors to euthanize people suffering from Alzheimer's, dementia, and other disease where the patient is unable to provide their consent.

According to LifeSiteNews, a Canadian health minister, Danielle McCann, said at a press conference earlier this month that the recommendation to allow the practice of euthanizing patients without their consent came from an "expert panel" that spent 18 months studying the issue.

However, McCann says that Qubec will launch its own non-partisan public consultation process before deciding whether to allow the practice.

"We have heard the the heartfelt appeal of Quebecers who are suffering and calling for a widening of the rules," McCann said, the Montreal Gazette reported. "Qubec society is evolving on this sensitive issue and we have a moral duty to respond. all together."

The advance assisted death directed would have to be authorized by the patient while they are still mentally able to decide. However, family members who disagree with their loved one's decision would "not have a veto," a committee member said at the meeting. Opponents of the measure also say that if someone were to change their mind, they could have no way of stopping their own death.

In the event a person suffers from a disease where they could lose their decision-making abilities, the Canadian panel recommended that patients formally designate a third party while they are still mentally capacitated who would inform doctors of the existence of a prior consent to be euthanized. The third party authorization would be kept in a government registry.

That third party would represent the patient should they lose their faculties due to diseases like Alzheimer's or dementia, but the final decision to euthanize the patient would rest in the hands of a physician.

The Gazette noted that a person in good health would be ineligible for requesting in advance to be euthanized should they were to suffer an unforeseen health incident, such as a heart attack or a car accident that leaves them paralyzed.

Under Qubec's current law, residents can only be euthanized if they meet all of the following criteria, according to LifeSiteNews:

McCann said the new measure gives patients "the freedom to decide and we do this while respecting their will, values and dignity."

Alex Schadenberg, executive director of the Euthanasia Prevention Coalition, disagreed and warned that the new policy may result in people being killed against their will.

"This is absolutely crazy, because it will allow euthanasia of someone who may never have wanted it, who might have in fear in an earlier state felt this was what they wanted, and when the time comes, they lose their right to change their mind," he told LifeSiteNews.

See more here:

New policy could allow doctors to euthanize Alzheimer's patients without their active consent - TheBlaze

Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board – P&T Community

NEW YORK, Dec. 17, 2019 /PRNewswire/ -- Hoth Therapeutics,Inc. (NASDAQ: HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announcedthe addition of Dr.William Weglicki, M.D. to the Company's Scientific Advisory Board. While serving on the Board, Dr, Weglicki will oversee Hoth's Aprepitant Program under its Scientific Research Agreement with the George Washington University ("GW").

Mr.Robb Knie, CEO of Hoth Therapeutics, commented, "I am pleased to welcome Dr. Weglicki to our Scientific Advisory Board.Dr. Weglicki will be instrumental towards the advancement of our Aprepitant program.Hoth is fortunate to have such well-respected leaders providing their invaluable expertise and insight to each of our significant research and development initiatives."

Dr. Weglicki isProfessor of Biochemistry and Molecular Medicine at the George Washington University School of Medicine.Dr Weglicki is a recipient of the Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery, The International Academy of Cardiovascular Sciences. After completing a medical residency at Georgetown University Hospital in 1964 he completed a Cardiology fellowship in 1966 at Duke University where he trained in clinical cardiac catheterization and pharmacology basic research. He was then appointed as a research associate at NIH's NICHHD and the McCollum Pratt Institute of the Johns Hopkins University where he studied the cardiac pathobiology of alpha tocopherol deficiency. In 1968 He joined Harvard's Peter Bent Brigham Hospital Department of Medicine's Cardiovascular Research unit, androse from Instructor to Associate Professor in 1975. There he concentrated his research on the role of phospholipases of the heart in the ischemic perturbation of cardiac membrane phospholipids and organelles, which led to several RO1 NIH grant awards. With his research team he moved to the Medical College of Virginia/VCU in 1975 as chairman of the Department of Biophysics and served as a professor of Medicine (Cardiology); there he was active in teaching medical and mentoring graduate students, while publishing a series of manuscripts on cardiac lysosomal activity in myocardial ischemia and the distribution of phospholipases in cardiac mitochondria and sarcolemmal membranes, and overseeing a new NHLBI Training Grant on molecular mechanisms of cardiovascular injury. At the Oklahoma Medical Research Foundation he led their Cardiovascular Research Program. He joined the George Washington University Department of Medicine in 1985 and formed the Division of Experimental Medicine; in 1987 this core group of investigators was awarded a Program Project grant on Molecular Mechanisms of Cardiovascular Injury from the National Heart, Lung, and Blood Institute. This research included identifying free-radical peroxidative injury during myocardial ischemia and the protective antioxidant properties of cardiac beta blocking drugs such as propranolol and carvedilol. At present he is a Professor of Biochemistry and Molecular Medicine and Medicine (Cardiology). He has been a principal investigator of NIH grants for more than thirty years. His ongoing research focuses on preventing neurogenic inflammation and hyomagnesemia effects associated with some anticancer drugs.

About Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. isa clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visitwww.hoththerapeutics.com.

Forward Looking StatementsThis press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period endingDecember 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

ContactsInvestor Relations Contact:Phone: (646) 756-2997Email:investorrelations@hoththerapeutics.comwww.hoththerapeutics.com

KCSA Strategic CommunicationsValter Pinto / Daniela Guerrero(212) 896-1254 / (212) 682-6300Hoth@kcsa.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-the-appointment-of-dr-william-weglicki-md-to-scientific-advisory-board-300976186.html

SOURCE Hoth Therapeutics, Inc.

Continued here:

Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board - P&T Community

Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D. – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, today announced the appointment of Neal Rosen, M.D., Ph.D., to its scientific advisory board (SAB). Dr. Rosen is a Member of the Molecular Pharmacology Program and the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).

Neals experience identifying and elucidating new molecular signaling pathways and understanding how to transform these early discoveries into effective drug development strategies fits perfectly with the work were undertaking at Ribon, said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. We see great untapped potential for the development of novel, first-in-class therapeutics that target the novel stress response pathways that many cancers rely on for survival, and working with experts such as Neal, who have successfully forged new paths in drug development will be invaluable.

Targeting stress response pathways to treat cancer has great potential, and shares similarities with the discovery and therapeutic targeting of kinase pathways, an area I have spent much of my career working to better understand and advance, commented Dr. Rosen. It is now understood that stress response pathways play a wide range of roles aiding cancer development and growth. I look forward to working with this truly pioneering team.

Ribon has done tremendous work taking its foundational discoveries and translating them into development programs, as evidenced by how quickly the Company was able to advance their lead program, RBN-2397, into the clinic, said Jim Audia, Ph.D., Chairman of the Ribon SAB. At this point in the Company's development, Neal is a fantastic addition to Ribons already stellar SAB, bringing his vast experience in the development and understanding of novel cancer targets and therapeutics to Ribon's developing pipeline.

Dr. Rosen's major interests involve identification and study of the key molecular events and growth signaling pathways responsible for the development of human cancers, and the use of this information for the development of mechanism-based therapeutic strategies. Dr. Rosen has pioneered the concepts that feedback inhibition of physiologic signaling is an important consequence of oncogene activation that shapes the phenotype of cancer cells and that relief of this feedback in tumors treated with inhibitors of oncoprotein-activated signaling causes adaptive resistance to these drugs. Recent work from the Rosen laboratory includes the elucidation of the underlying mechanisms whereby mutated BRAF genes cause cancer and the discovery that these mutations may be divided into three different classes that determine the effective strategies for their treatment. These studies predicted several of the cellular mechanisms whereby tumors develop acquired resistance and adaptive resistance to standard therapy and the discovery and development of new drugs that will reverse this resistance. Recently, the Rosen laboratory has also focused on the development of the first direct inhibitor of RAS, a gene involved in the development of 25% of human cancers. This work, in addition to other recent studies by the Rosen laboratory on the consequences of relief of negative feedback by oncoprotein inhibitors, has led to multiple clinical trials of combination therapies at Memorial Sloan Kettering and other cancer centers in the United States and internationally that have shown promising early results. He is the incumbent of the Enid A. Haupt Chair in Medical Oncology at MSK and the recipient of the Lifetime Achievement Award from the Society for Melanoma Research.

Dr. Rosen received his undergraduate degree in chemistry from Columbia College and an M.D. and Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. He completed a residency in Internal Medicine at the Brigham and Womens Hospital, and postdoctoral training and a fellowship in Medical Oncology at the National Cancer Institute. He was on the senior staff of the Medicine Branch at the NCI prior to joining the faculty of MSK.

RBN-2397 Inhibiting PARP7, a Key MonoPARP Cancer Dependency

Ribons lead program, RBN-2397, is focused on inhibiting overactive PARP7 in tumors, which has been shown to play a key role in cancer survival. Ribons research has discovered that many cancer cells rely on PARP7 for intrinsic cell survival, and that PARP7 allows cancer cells to hide from the immune system. Ribon has demonstrated that inhibition of PARP7 with RBN-2397 can potently inhibit the growth of cancer cells and restore interferon signaling, effectively releasing the brake cancer uses to hide from the immune system and suppress both innate and adaptive immune mechanisms. In several cancer models, RBN-2397 demonstrated durable tumor growth inhibition, potent antiproliferative activity and restoration of interferon signaling. Ribon plans to initially develop RBN-2397 in squamous cell carcinoma of the lung, where research has shown PARP7 to be genetically amplified. The company also plans to explore RBN-2397 for the treatment of additional cancers, including cancers of the aerodigestive tract, pancreatic cancer and ovarian cancer.

PARP7 is a member of the monoPARP family of proteins, which are key regulators of stress responses that enable cancer cells to survive and also evade immune detection, and emerging science has linked their activity with disease development. MonoPARPs are a family of 12 enzymes that are functionally and structurally distinct from the more well-known polyPARPs, such as PARP1/2. MonoPARPs function across a variety of stress responses relevant to disease development in cancer, inflammatory conditions and neurodegenerative diseases. Ribon has built an integrated technology platform to interrogate monoPARPs to develop first-in-class, small molecule therapeutics.

About Ribon Therapeutics

Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and our proprietary discovery platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a first-in-class PARP7 inhibitor in development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts. For more information, please visit http://www.ribontx.com.

See the original post:

Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D. - Business Wire

iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming – Yahoo Finance

- Presentation Demonstrates Advantages of iBios Recently Launched FastGlycaneering Development Service -

NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) presented results of the application of its new FastGlycaneering Development Serviceto enhance potency of recombinant proteins at last weeks Antibody Engineering & Therapeutics conference in San Diego, CA. Specifically, the presented data demonstrated the ability to deploy iBios glycan engineering technologies and plant-based manufacturing platform to rapidly develop and produce biobetters, such as the biobetter rituximab (iBio Rituximab) product candidate currently being developed in collaboration with CC-Pharming Ltd.

Dr. Sylvain Marcel, iBios Vice President of Protein Expression Sciences, highlighted laboratory results showing how iBios FastGlycaneering Technology enables greater N-linked glycosylation customization and control. In the case of iBio Rituximab, antibody dependent cellular cytotoxicity was increased 30-fold; potency, as measured by half maximal effective concentration, was substantially improved versus the control antibody; and iBios glycan engineering methods were shown to be capable of producing antibodies with more homogeneous and fully human glycosylation patterns.

This study demonstrated that our complementary glycan engineering technology can improve the activity of therapeutic antibodies, which is instrumental in the development of antibodies with higher potency, stated Dr. Marcel. These data represent a very positive development within our collaboration with CC-Pharming and, in addition, highlight iBios ability to produce antibodies with more homogeneous and humanized glycosylation patterns, which can help our other clients and partners achieve their target product profiles.

In addition to joint work on a biobetter rituximab, iBio and CC-Pharming are undertaking joint product assessments in other categories that, in some cases, may reach the commercial stage faster than is possible with therapeutic antibodies. The companies expect to use iBios FastGlycaneering Technology for any glycoproteins selected from the initial candidate pool for advancement to commercial development.

In August 2019, iBio granted to CC-Pharming an exclusive, royalty-bearing commercial license to iBio Rituximab product candidates for the territory of China, as well as a research license to iBios FastPharming System and know-how for the evaluation of multiple product opportunities.

About CC-Pharming Ltd.

CC-Pharming is located in Zhongguancun Biomedical Engineering Transformation Center, Shunyi District, Beijing, China. The company is specialized in plant molecular medicine technology research and product development using proprietary tobacco and lettuce transient expression platforms, focusing on the use of plant bioreactors for the development of animal-free, safe, high-value recombinant protein and peptide product for industrial and clinical applications. The Company develops innovative indoor vertical farming system for efficient plant-based expression systems, and offers therapeutic biomedicine, life science research, cosmetics, and CRO/CMO services to clients in China. Further information is available at http://www.cc-pharming.com.

About iBio

iBio, Inc., is a global leader in plant-based biologics manufacturing. Its FastPharming System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Companys subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas. iBio CDMO also enables innovators to use the FastPharming System for insourced manufacturing via its Factory Solutions design-and-build services. iBios FastGlycaneering Development Service includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing its own proprietary products which include its lead asset, IBIO-100, for the treatment of fibrotic diseases. For more information, visit http://www.ibioinc.com.

Story continues

FORWARD-LOOKING STATEMENTSSTATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen KilmerInvestor Relations(646) 274-3580 skilmer@ibioinc.com

Continue reading here:

iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming - Yahoo Finance

Engineered Protein Assemblies that Respond to Cues Open Path for Smart, Protein-Based Medicines | Newsroom – UC Merced University News

By Michelle Morgante, UC Merced

Proteins are miniscule machines inside the body, about 10,000 times smaller than the thickness of human hair. They control all the processes of life like how cells communicate to each other, how the immune system combats infection, how muscles contract, and how oxygen is picked up in the lungs and delivered to those very same muscles.

Proteins can do all of this because they change shape, assemble and interact with other biomolecules in response to specific cues. This general property makes proteins extremely attractive targets for a variety of applications in medicine, environment, food industry and energy. But it also has proven very difficult to harness. Now, bioengineering Professor Victor Muoz has made a key discovery that could allow scientists to engineer adaptive proteins and convert them into powerful technological applications, including smart medicines.

In a paper published Dec. 13 in Nature Communications, Muoz and a team of researchers describe how they were able to engineer proteins to form assemblies, dissociate and change shape in response to signals. The discovery could allow scientists to, for example, use proteins to deliver drugs in a way that is less toxic and more targeted than current practices.

Proteins in their natural state are easily passed through the kidney, meaning they are not in the blood long enough to act as an effective medicine.

But when a protein makes an assembly, Muoz said. It forms structures that are larger and sturdier and dont get secreted out of the kidney. They stay in the blood for a longer time.

Muoz, who is director of UC Merceds Center for Cellular and Bio-Molecular Machines (CCBM-CREST), said research for this project began a decade ago and has involved collaboration from several groups around the world. The work to figure out how to engineer proteins to act as nanomachines has been challenging and tortuous.

They do all these complicated things and are so small. That means their design principles and organization are incredibly sophisticated, he said. People have been able to design proteins that will form particular assemblies of many different shapes, but they have not been able to make them adaptive so they switch their shape and properties in response to stimuli.

"This opens the gate for developing drugs that are based on proteins in a way they could be delivered as inactive assemblies that remain in the blood as needed to then be activated on cue at a given time or in a specific location in the body."

director, Center for Cellular and Bio-Molecular Machines

The discovery may lead to important applications in biosensor research, medicine, diagnostics, vaccines, bioremediation anything you could imagine, Muoz said.

In medical applications, for example, proteins engineered this way could become a new technology for the smart delivery of specific drugs.

This would have enormous advantages over conventional drugs, which are much less specific, more toxic and can cause a range of harmful side-effects. It could also help store an inactive version of the protein in blood for a relatively long time, eliminating the short lifespan curse of current protein pharmaceuticals.

This opens the gate for developing drugs that are based on proteins in a way they could be delivered as inactive assemblies that remain in the blood as needed to then be activated on cue at a given time or in a specific location in the body, Muoz said.

The next step, Muoz said, will be to try the process in other systems and see whether it can be generalized. This was a proof of concept. Next, wed like to target systems that have more interesting applications to exploit the possibility of making this into a real technology thats useful.

Read this article:

Engineered Protein Assemblies that Respond to Cues Open Path for Smart, Protein-Based Medicines | Newsroom - UC Merced University News

Experts Forum: Creating a cluster of innovation in Rochester – Finance and Commerce

Click on the image above to see the full magazine.

Innovation being synonymous with Mayo Clinic is nothing new. But now, thanks to Rochesters massive, multiyear undertaking to present the entire city as a beacon for innovators and entrepreneurs, the whole region 75 miles south of the Twin Cities is poised for a technological and economic renaissance.

Finance & Commerce recently hosted a panel discussion about what Rochesters future might hold in those regards. The chat took place at One Discovery Square in Rochester.

The panelists included:

Executive director, Collider Foundation

Traci Downs

President and CEO, Medical Alley Association

Shaye Mandle

Medical director of business development and dermatologic surgeon, Mayo Clinic

Dr. Clark Otley

President and CEO, Vyriad; professor, Mayo Clinic

Dr. Stephen Russell

Director of business development, Discovery Square

Chris Schad

Co-founder and general partner of Capita3

Pam York

Continue reading here:

Experts Forum: Creating a cluster of innovation in Rochester - Finance and Commerce

Westmead advanced manufacturing to transform lives – News – The University of Sydney

A vector is a microscopic carrier of pieces of DNA. It is used to deliver healthy copies of genes to tissues and organs within patients or deliver the ability to correct the genetic errors. While the technology is moving rapidly, production of vectors is not.

NSW, and in particular the Westmead Precinct, is already at the forefront of international gene therapy research. The aim of this project is to speed up research and translate it into cures for serious genetic diseases affecting children.

The facility will produce vectors to treat illnesses impacting everything from those with life-threatening liver disease to children going blind. Currently the vectors need to imported and its extremely costly to get them to Australia.

Professor Ian Alexander, Head of the Gene Therapy Research Unit at Childrens Medical Research Institute, senior clinician at The Childrens Hospital at Westmead and Professor of Paediatric and Molecular Medicine at the University of Sydney, said the manufacturing facility would be a boost to translation of academic research in NSW.

We see it as the beginning of something much greater, Professor Alexander said.

It is about moving technology into the clinic, which, in future, will benefit many more patients by offering new and better treatment opportunities. This technology could translate into saving the lives of infants with life-threatening conditions.

Dr Leszek Lisowski heads the Translational Vectorology Group at CMRI and is Conjoint Senior Lecturer at the University of Sydney. His team will play a key role in the new facility, through training of staff and developing the manufacturing processes that will underpin operations. In addition, his team specialises in the development of novel vectors optimised for clinical applications targeting liver, eye and many other clinically important organs and tissues.

Dr Lisowski said that this new facility will allow Australian investigators to get around the "bottleneck" of getting vectors from overseas.

The biggest bottleneck that slows down translation of gene therapy tools to the patient is a global lack of vector manufacturing capacity, which significantly extends the timeline and increases the cost of translational studies," he said.

This facility will give Australian researchers prioritised and cost-effective access to clinical gene therapy reagents and will facilitate translation of a large number of exciting preclinical programs from bench to bedside.

The team is excited by this vital investment and looks forward to partnering with government and other funders to enable the facility to achieve its full potential.

The Westmead Precinct is one of the largest health, education, research and training precincts in Australia and a key provider of jobs for the greater Parramatta and western Sydney region. Spanning 75 hectares, the Precinct includes four hospitals, four world-leading medical research institutes, two multidisciplinary university campuses and the largest research-intensive pathology service in NSW.

The University of Sydney has long been a proud partner of the Precinct and is in negotiations about developing a second major campus in the area. By 2050, that campus will include 25,000 students; 1000 staff and researchers; generate $21.7 billion for the NSW economy and support up to 20,000 jobs.

University of Sydney Vice-Chancellor and Principal Dr Michael Spence said that as part of our collaborative work in building a western Sydney global centre of excellence, Precinct partners are growing Australias advanced manufacturing capability.

These developments will strengthen crucial collaborations in the Precinct from R&D and design to distribution in areas such as prevention and wellbeing, biomedical engineering, AI and personalised medicine, Dr Spence said.

Faculty of Medicine and Health Executive Dean Professor Robyn Ward said: This technology will scale up gene therapy using viral vectors from single-condition, life changing successes, for example in spinal muscle atrophy, to a national service.

We are so proud of this leadership at the Westmead Precinct and with our health partners. It is a whole-of-lifespan, true bench-to-clinic approach."

Follow this link:

Westmead advanced manufacturing to transform lives - News - The University of Sydney

Native Hawaiian health focus of graduating JABSOM PhD – UH System Current News

Christian Dye

A graduate student in the University of Hawaii at Mnoa John A. Burns School of Medicine (JABSOM) is conducting research that may have a significant impact on underserved and vulnerable populations. Christian Dye is probing the causes of diabetes and other chronic diseases prevalent in Native Hawaiian and other communities.

Dye, currently a faculty member at JABSOM, will earn his PhD from UH Mnoa in spring 2020.

My current research seeks to understand inflammation-associated disorders, like diabetes, from an epigenetics viewpointthe influence of environmental factors (diet, exercise, smoking, etc.) on how our cells function by influencing how genes are turned on, off, or even changed, he explained.

JABSOM has allowed me to be at the center of research that is not only meaningful, but was instrumental in allowing me to do so in the communities that I feel most passionate about, Native Hawaiians and Pacific Islanders, Dye said.

Dye focuses on epigenetics to determine the potential mechanisms underlying disease pathogenesis. We may be able to understand whether certain areas of the genome are epigenetically regulated and if such regulation may be involved in how immune cells function and whether this leads to immune dysfunction or inflammation.

Exciting results of Dyes research include the benefits of an intervention in Native Hawaiians with diabetes, which led to drastic changes in epigenetic profiles. The epigenetic alterations were linked to changes in gene expression and immune cell function (reduced inflammation) that were associated with better glycemic control. These findings have potentially bridged cell function and beneficial health outcomes with epigenetic modifications that may regulate genes enriched in biological functions important to immune cells, he said.

Dye plans to develop a network of community-based participatory research centers for investigation of cellular, molecular or biological mechanisms that may underlie the benefits of culturally-based practices and interventions. By bridging indigenous knowledge and practice within a western context of science, technology and medicine, we may be able to understand the science as to why these practices are beneficial to at-risk communities while also elucidating how certain cells, like immune cells, may function, and the potential that their regulation may be involved in beneficial health outcomes which can eventually be used in targeted strategies for understanding disease risk and possible therapeutics.

Dyes interest in the cellular and molecular biology of health disparities motivated him to work at the UH medical school. JABSOM has allowed me to be at the center of research that is not only meaningful, but was instrumental in allowing me to do so in the communities that I feel most passionate about, Native Hawaiians and Pacific Islanders, he said. JABSOM also allowed me to enter some of the communities where these health disparities are prevalent and use research to help understand them.

Read more on the JABSOM website.

See the original post:

Native Hawaiian health focus of graduating JABSOM PhD - UH System Current News

DTR’s news round-up 2019: the stories that defined the year – Drug Target Review

Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.

Drug Target Review has published a wide range of news stories this year, from the identification of novel drug targets to improvements in toxicology studies and developments in screening.

As the year draws to a close, we reflect on the biggest and most popular stories from 2019. To read the full pieces, click on the title of each news story.

A genetic analysis study revealed that variants of hundreds of genes work together in contributing to the development of Tourettes syndrome, in our tenth most popular story this year.

According to the researchers, from the Massachusetts General Hospital (MGH) and collaborators, their findings confirm that the underlying basis for Tourettes syndrome is polygenic, meaning that hundreds of small DNA changes cause the condition, rather than one inactive gene.

The scientists said their next step is to expand their sample size to around 12,000 patients, made possible with a potential international collaboration.

The study was published in the American Journal of Psychiatry.

A group of researchers identified new genetic targets on which BRCA2-driven cancer cells are dependent upon, providing a potential avenue for drug development.

The study, conducted at Brigham and Womens Hospital, used CRISPR and short-hairpin RNAs (shRNAs) to test 380 genes with a known or suspected role in DNA-damage response. This allowed the team to narrow in on the most promising genes: APEX2 and FEN1, two novel targets for breast cancer.

The results were published in Molecular Cell.

Immunotherapy treatment could reduce the persistence of HIV in patients receiving triple therapy, found a group of researchers.

The researchers, from the University of Montreal Hospital Research Centre, discovered that these therapies expose the virus to the immune system. Three proteins PD-1, LAG-3 and TIGIT were uncovered by the scientists as frequently expressed on the surface of HIV-hiding cells; these proteins are also cancer targets.

According to the team, their study could lead to the development of new HIV therapies based on cancer immunotherapies.

The study was published in Nature Communications.

Researchers at the Indiana University School of Medicine developed a blood test to measure pain and improve diagnosis. The team analysed hundreds of patient samples to reveal biomarkers in their blood, which could be used as a scale to determine pain.

According to the researchers, the biomarkers act like a signature that can be matched against a prescription database. This could allow medical professionals to select the appropriate compound and reduce pain for the patient.

The study was published in Molecular Psychiatry.

A team of scientists revealed that immune cells could be key in causing endometriosis, a pelvic pain experienced by women, through an investigation into macrophages. The study was led by researchers from Warwick Medical School and the University of Warwick.

Macrophages can adapt their function according to local signals from their surroundings and so become modified by disease. This led the researchers to add modified macrophages to a cell culture, which resulted in the production of higher levels of insulin-like growth factor-1 (IGF-1).

The team conclude that macrophages therefore present a drug target for endometriosis.

The results can be found in The FASEB Journal.

Scientists from the University of Pennsylvania imaged a molecule that induces inflammation and leads to lupus, in our fifth most popular story of 2019. The researchers discovered that the molecule is comprised of two sections: SHMT2 and BRISC, a cluster of proteins. When these two sections bind to each other, they cause inflammation.

When mice models lacking BRISC were tested, they were resistant to lupus. This led the team to conclude that a molecule which blocks BRISC and SHMT2 could be a drug target for lupus.

The findings were published in Nature.

A team of researchers reported that a CRISPR-Cas9 gene therapy which specifically reduces fat tissue and obesity-related metabolic disease was successful in mice.

The scientists, from Hanyang University, argue that their technique could be used as a way to combat type 2 diabetes and other obesity-related diseases.

Targeting Fabp4, a fatty acid metabolism gene, the researchers observed a 20 percent reduction of body weight in obese mice. It also resulted in improved insulin resistance after only six weeks of treatment.

The findings were published in Genome Research.

A compound that promotes the rebuilding of the protective sheath around nerve cells has been developed by researchers at the Oregon Health & Science University (OHSU).

The team found that the S3 compound reverses the effect of hyaluronic acid (HA) in mice. HA has been found to accumulate in the brain of patients with multiple sclerosis, and accumulation of HA

has also been linked to maturity failure of cells called oligodendrocytes, which generate myelin, the protective layer of axons.

The team therefore believe that the S3 compound could provide a therapeutic strategy for treating nervous system disorders.

The study can be found in Glia.

A group of researchers formed a complex view of the functional dysbiosis in the gut microbiome during inflammatory bowel disease (IBD), to reveal new targets for treatments.

The scientists, from theBroad InstituteofMITandHarvard University, observed microbial changes and human gene regulatory shifts from stool and blood samples of patients.

This multi-omic study enabled the team to discover that during periods of disease activity, IBD patients had higher levels of polyunsaturated fatty acids in both the blood and stool. They also identified other varying levels of nutrients and vitamins, presenting several potential drug targets.

The findings were published in Nature.

In our most popular news piece this year, researchers found that the small molecule PJ34 reduces the number of human pancreatic cancer cells in transplanted tumours by 90 percent.

The team, from Tel Aviv University, built on previous research to treat xenografts with their small molecule. It is permeable in the cell membrane, but affects human cancer cells exclusively, making it an attractive compound for development.

The scientists found that PJ34 causes a rapid cell death and in one mouse, the tumour completely disappeared. They concluded that the molecule could be a potent therapeutic against pancreatic cancer.

The results were published in Oncotarget.

Related organisationsBrigham and Women's Hospital, Hanyang University, Harvard University, Indiana University School of Medicine, Massachusetts General Hospital (MGH), MIT, Oregon Health & Science University (OHSU), Pennsylvania University, Tel Aviv University, University of Montreal Hospital Research Centre, Warwick Medical School, Warwick University

The rest is here:

DTR's news round-up 2019: the stories that defined the year - Drug Target Review

Graduating with a master’s degree AND a medical discovery – Science at ANU

For her masters degree in biotechnology, Pallavi Venkatesh didnt just learn about the latest advances in medical science, she made some too.

Pallavi studied one of the most important tools in modern medicine, the Vaccinia virus, which was used as a vaccine to eradicate smallpox.

I found out that different strains of the virus preference different pathogen-sensing molecules found within immune cells, which is really exciting, she says.

Better understanding how different virus strains are detected by immune cells could help fine-tune its use as a tool against cancers and other viruses in the future.

Our finding was exciting as we found that more than one of these pathogen sensor molecules was involved and that different strains may activate different sensor molecules preferentially.

Pallavi says the coursework components of her Master of Biotechnology (Advanced) at The Australian National University (ANU) gave her the skills she needed to undertake this original research.

I studied genomic sciences, molecular biology and cell biology, which I really enjoyed, she says.

For the research component of her degree, she had the opportunity to be part of an innovative team at The John Curtin School of Medical Research (JCSMR).

I did my research under David Tscharke in the Immunology Department, she says.

Working with David was an amazing learning opportunity, he pushes you to be the best you can and provides incredible support.

I also received additional support from members of the lab which helped me through my research year.

Prior to arriving at ANU, Pallavi completed her undergraduate degree at Jyoti Nivas College in Bangalore.

She says that Canberra and living on campus at Toad Hall provided the ideal environment for a postgraduate scholar.

I highly recommend ANU as a place to study, she says. I made lots of new friends here, friends for life.

Inspired by her time at JCSMR, Pallavi is now planning to pursue a career in immunology.

Find out more about how a Master of Biotechnology at ANU can help launch your career in medical, biological or agricultural science.

Continue reading here:

Graduating with a master's degree AND a medical discovery - Science at ANU

IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors – BioSpace

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the appointment of Wendy L. Yarno as a Director of its Board of Directors.

Ms. Yarno spent 26 years at Merck & Co. in commercial and human resource positions of increasing seniority, including most recently as Executive Vice President and Chief Marketing Officer. She previously served as General Manager, Cardiovascular / Metabolic U.S. Business Unit and as Executive Vice President, Worldwide Human Health Marketing. In these roles, Ms. Yarno developed deep expertise in pharmaceutical commercialization, including drug development, regulatory strategy, market development, global product strategy and product life-cycle management.

Ms. Yarno currently serves on the board of directors of publicly traded life sciences companies Global Blood Therapeutics, Inovio Pharmaceuticals, Inc. and Myokardia. She previously served on the board of directors of various other life science companies, including Alder Biopharmaceuticals, Durata Therapeutics, St. Jude Medical and Medivation.

"Wendy brings a unique breadth of experience in pre-and post-launch commercialization of pharmaceuticals to our Board," said John Diekman, Ph.D., Chairman of IDEAYA's Board of Directors.

Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences observed that "Wendy's commercial experience and leadership will be invaluable to IDEAYA, in particular as we advance clinical development of our lead clinical development program, IDE196, into a potentially registration-enabling single-arm Phase 2 clinical trial in metastatic uveal melanoma, anticipated in first quarter 2020."

"I'm delighted to join IDEAYA's Board of Directors to help advance IDEAYA's vision of improving lives through transformative precision medicines. I am excited to contribute to IDEAYA's pipeline of precision medicine oncology therapeutics, including approaches directly targeting oncogenic pathways and synthetic lethality an emerging class of precision medicine targets," said Ms. Yarno.

About IDEAYA BiosciencesIDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality which represents an emerging class of precision medicine targets.

Forward-Looking StatementsThis press release contains forward-looking statements, including, but not limited to, statements related to expected timing for advancing clinical development of IDE196 into a potentially registration-enabling single-arm Phase 2 clinical trial in metastatic uveal melanoma. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on November 13, 2019 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-wendy-yarno-to-its-board-of-directors-300976587.html

SOURCE IDEAYA Biosciences, Inc.

Company Codes: NASDAQ-NMS:IDYA

See original here:

IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors - BioSpace

Angion Initiates Dosing in Phase 1 Clinical Trial Evaluating ANG-3070, a Dual-Kinase Inhibitor for the Treatment of Fibrotic Diseases – GlobeNewswire

SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing first-in-class therapies to treat acute kidney injury and other types of organ damage, today announced it dosed the first participant in a Phase 1 clinical trial evaluating ANG-3070 in healthy volunteers. ANG-3070 is an orally bioavailable small molecule intended for development as a potential treatment for idiopathic pulmonary fibrosis, primary focal segmental glomerulosclerosis (FSGS) and a variety of other fibrotic diseases.

We are pleased to announce the first participant dosed in this Phase 1 healthy volunteer trial investigating the safety and tolerability of ANG-3070. Entering the clinic is an important milestone for ANG-3070, our precision drug candidate, which has already demonstrated in vivo proof-of-concept in a variety of animal models as an anti-fibrotic agent, said Jay Venkatesan, M.D., Chief Executive Officer. This is an important step in establishing the safety profile of a potential treatment for a variety of fibrotic diseases proven difficult to treat or for which there are no approved therapies.

This Phase 1 randomized, double-blind, placebo-controlled study will primarily assess the safety, tolerability, pharmacokinetics and food effect of ANG-3070 in healthy adult subjects. Angion expects this Phase 1 healthy volunteer trial to complete enrollment in the first half of 2020 and anticipates presenting full data at scientific meetings after trial completion.

About ANG-3070ANG-3070 is an orally bioavailable small molecule fibrokinase inhibitor under development for the treatment of chronic fibrotic diseases. ANG-3070 has exhibited preferential activity against molecular pathways involved in and associated with poor outcomes of pulmonary and renal fibrosis. ANG-3070 is currently being developed as a precision medicine guided therapy for pulmonary fibrosis and primary focal segmental glomerulosclerosis.

About Angion Biomedica Corp.Angion Biomedica Corp. is a clinical stage biopharmaceutical company focused on developing novel therapeutics for serious, life-threatening conditions without adequate therapeutic options. The Companys lead clinical asset, ANG-3777, is engineered to activate the HGF/c-Met pathway, an important mechanism in organ repair. Enrollment is ongoing in a placebo-controlled Phase 3 trial examining the efficacy of ANG-3777 in reducing the severity of delayed graft function after kidney transplant. Angion is also developing ANG-3070, an oral small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach. For further information, please visit http://www.angion.com.

Media ContactCherilyn Cecchini, M.D.LifeSci Public Relations646-876-5196ccecchini@lifescipublicrelations.com

Originally posted here:

Angion Initiates Dosing in Phase 1 Clinical Trial Evaluating ANG-3070, a Dual-Kinase Inhibitor for the Treatment of Fibrotic Diseases - GlobeNewswire

Triple Negative Breast Cancer Recurrence Prediction Method Developed – Clinical OMICs News

Triple negative breast cancer is one of the most difficult types of breast cancer to treat, due to the mechanism being undefined. It is negative for the three most commonly mutated breast cancer markers: HER2, estrogen receptors, and progesterone receptors. It is one of the most aggressive and deadliest types of breast cancer because it lacks common traits used to diagnose and treat most other breast cancers. This lack of definition also makes it difficult to predict the outcome of treatment.

However, researchers at Indiana University have developed a new bioassay that can better predict triple negative breast cancer outcomes, particularly the likelihood cancer recurrence and survival.

Milan Radovich, Ph.D., and Bryan Schneider, M.D., discovered that of women whose blood plasma contained genetic material from a tumor (circulating tumor DNA known as ctDNA), 56% were likely to be cancer-free two years following chemotherapy and surgery. Patients who did not have ctDNA in their plasma had an 81% likelihood to not have cancer return after the same amount of time. The researchers recently presented their findings at the San Antonio Breast Cancer Symposium.

This study, a part ofIndiana Universitys Precision Health Initiative Grand Challenge for triple negative breast cancer, also examined the impact of circulating tumor cells (CTC), live tumor cells released from tumors into the surrounding blood and lymph, on recurrence.

What we found is if patients were negative for both ctDNA and CTC, 90% of the women with triple negative breast cancer remained cancer-free after two years, said Radovich, who is lead author of this study.

The two researchers, along with colleagues from the Hoosier Cancer Research Network, based their findings on analyzing the plasma from blood samples of 142 women with triple negative breast cancer, at stage I, II or III. These women had previously undergone chemotherapy prior to surgery, and were participants in another study testing genomically directed therapy. When doctors used FoundationOne Liquid to test for ctDNA levels, 90 of the women tested positive and the remaining 52 were negative.

Detection of ctDNA was also associated with poor overall survival. Specifically, the study showed that patients with detectable levels of ctDNA were four times more likely to die from the disease when compared to those who tested negative for ctDNA.

The authors say the next step is a new clinical study expected to begin in early 2020, which leverages this discovery to enroll patients who are at high risk of breast cancer recurrence to evaluate new treatment options for them.

Just telling a patient they are at high risk for reoccurrence isnt overly helpful unless you can act on it, said Schneider, who is senior author. Whats more important is the ability to act on that in a way to improve outcomes.

Radovich says each triple negative breast cancer case is unique. Each one has its own set of mutations that cause that cancer and drive it and its really through advances in precision medicine that were able to tailor therapy the best we can to treat these patients. Moving forward, what we know is that the technology is rapidly advancing. Our ability to detect the circulating tumor DNA is actually quite good now, but its getting better even with advances in technology.

We were able to actually look at both in this case, how ctDNA and CTCs may work together to determine which patients will relapse and which will not, said Radovich, who also said the capability to examine a patients plasma for tumor mutations has only been around for the past three years.

What I think were proud of here at IU is that were already applying this for clinical care. Were using this actively for our patients here at the IU Simon Cancer Center, as well as in clinical trials and were proud that were really providing our patients the most cutting-edge technology available on the planet.

Doctors and scientists arent the only ones who are excited by the latest breakthrough in triple negative breast cancer.

Nadia Miller, a 12-year triple negative breast cancer survivor and president of Indianapolis-based breast cancer advocacy group Pink-4-Ever, says she and the community are excited about the implications of the discovery as well.

Specifically for patients, and then just what the researchers are doing, it gives us very intentional data to use for the recovery and the survivorship of a persons life, said Miller. So I think what they are doing is just laying the foundation for years and years to come. The communitys response to this is that theyre hopeful. Theyre hopeful to see whats next and just really excited about this groundbreaking information.

She went on to say, This is a huge leap toward more favorable outcomes and interventions for triple negative breast cancer patients.

Link:

Triple Negative Breast Cancer Recurrence Prediction Method Developed - Clinical OMICs News

Did Schiff Poke a Hole in the First Amendment? – The New York Times

Last week, the House Judiciary Committee debated articles of impeachment drawn from a densely argued, sharply worded 300-page report that the Democratic majority on the House Intelligence Committee produced. It is an investigative tour de force, written for posterity. In considerable detail, using interviews and records, it describes, for example, how President Trumps top personal adviser, Rudolph W. Giuliani, traipsed across Europe, circumventing diplomats as he furthered the presidents direct political interests. It also delves into the circumstances behind Mr. Giulianis repeated contacts with a reporter, John Solomon of The Hill, and marshals a case that Mr. Solomons reporting helped push a false and damaging narrative about the then-serving American ambassador to Ukraine, Marie Yovanovitch.

The committee chairman, Representative Adam Schiff, believed that a detailed description of Mr. Solomons contacts with Mr. Giuliani and with Ukrainians were germane to the core of the case for impeachment against Mr. Trump, because the report speaks to the flood of misinformation that may have persuaded President Trump to act so recklessly.

But those who care about the vitality of journalism should here take a pause and ask why they dont feel disturbed. John Solomons investigative articles for The Hill may have been wrong, they were often misleading, and they were (judiciously, unwittingly?) used to further a conspiracy to oust a respected American ambassador. Mr. Solomon is a dogged, prideful investigator who worked with The Associated Press and The Washington Post before his political inclinations became more manifest and his penchant for accepting conclusions congenial to Republican partisans became a calling card.

But in revealing whom Mr. Solomon talked with, and when, Mr. Schiff and his committee have created a new pathway for the government to find and reveal a reporters sources and to question his or her motives. That is wrong. The legislative branch should not use its subpoena power to police journalism.

Mr. Schiffs pathway could easily be considered a precedent. And the government does not need more encouragement to out a journalists sources. The executive branch, in the institutions of the Department of Justice and the F.B.I., has used metadata call records and routing information not protected by the Fourth Amendment to document reporters contacts with their sources in a number of cases in which the source has subsequently been imprisoned. The public interest case for prosecuting leakers is easy to make. But we should note that the governments obligation to protect national security and a reporters duty to uncover abuses of executive power often clash. Whom you side with at those junctures depends on which tribe you belong to. Im a journalist, so I often side with the journalists.

I do have a big problem when journalists wittingly or unwittingly collude with foreign governments to degrade the institutions of democracy that we rely on. And while Im tempted to assert that Congress has no business ever poking its nose into reporting, I cant deny the circumstances that collided here; Mr. Solomon is part of this story. But to deny him any First Amendment protection of his work is to fail to see beyond the immediate ramifications of Mr. Schiffs decision. If Republicans regain control of the House, what would prevent them from using the same tactic to pummel the press for stories its members dont like? Ah, but what if the reporters have been consorting with liars and cons, as seems to be the case here?

Well, the worst people often have the best available information, and judgment calls are a humble part of the journalistic enterprise. Congress should recognize this and acknowledge that it is important.

Mr. Schiff did not subpoena Mr. Solomon directly, and his staff seems to believe that this settles the matter. But it should not. Mr. Schiff has effectively punished a reporter for reporting. And punishments that might be levied for errors in reporting and for apparent partisan bias should never come from the government. Journalists who dont object to this investigative practice will conspire to make it much easier for future entities in government to harass reporters who are pursuing the truth.

It pains me to see some of our most respected advocates for press freedom default to the view that Congresss procedures were duly followed and, while there may be some ickiness in the air, Republicans who have complained about Mr. Schiffs methods have no right to complain about intrusive government. This argument does not track, though, especially during a week when the Justice Departments inspector general revealed serious and potentially material deficiencies in the F.B.I.s application to renew a Foreign Intelligence Surveillance Act order against Carter Page, a low-level Trump foreign policy aide whom the F.B.I. suspected might have a been a conduit for the Russian government to control or influence the Trump campaign. (There is no evidence that Mr. Page, a serial entrepreneur with some dubious friends, served in this role.)

Another way to minimize the First Amendment implications of Mr. Schiffs decision is to note that President Trump represents (and indeed has become) a far worse threat to a free press than any consequence of a procedurally appropriate congressional investigation. I agree with the statement of value: that Mr. Trump has beguiled, bewildered and bullied the press to a point of real danger. Labeling the press the enemy, arguing for looser libel laws, threatening broadcast licenses, gleefully encouraging his followers worst assumptions about the role of reporters all but invites us to consider him a national security threat the way some of his own appointees came to. But Trump being Trump is not an excuse for lowering the threshold for First Amendment vigilance elsewhere. Indeed, we should raise our voices even louder when other institutions of government make public a more casual appreciation of the First Amendment. Making sure that Congress passes rules that limit the use of subpoenas to inspect or reveal reporter-source relationships should be a priority.

Much of what the public knows about President Trumps conduct in office comes from journalists who have not been cowed by the enormous power wielded by the executive branch and its investigative capabilities. The civic emergency within which we are working will be exacerbated if we excuse or brush off an abuse of power because it supports our side.

Marc Ambinder (@marcambinder) leads the Annenberg digital security initiative at the University of Southern California. He also teaches national security reporting.

The Times is committed to publishing a diversity of letters to the editor. Wed like to hear what you think about this or any of our articles. Here are some tips. And heres our email: letters@nytimes.com.

Follow The New York Times Opinion section on Facebook, Twitter (@NYTopinion) and Instagram.

See the original post here:

Did Schiff Poke a Hole in the First Amendment? - The New York Times